The sublicensee is a Ugandan manufacturer and the sublicence permits local development and manufacture for the licence's country list, so the transaction is African by party domicile and manufacturing location. Qcil is described as the only East African sublicensee.
| Record ID | TX-AFR-2026-0021 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Sublicence, Patent licence, Technology transfer, In-licensing |
| IP rights | patent, know-how, regulatory data |
| Status | Signed |
| Qualifying date | 2026-09-16 |
| Sector | Life sciences · Pharmaceuticals – antivirals |
| African markets | Uganda |
| Licensed territory | Countries covered by the MPP-Roche baloxavir licence (129 low- and middle-income countries), subject to regulatory authorisation. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, independently corroborated · 3 source(s) |
| Last verified | 2026-10-25 |
Parties
- Medicines Patent Pool Foundation (Switzerland): sublicensor
- Quality Chemical Industries Limited (Qcil) (Uganda): sublicensee, manufacturer
Key terms
- Interest: sublicence; Exclusivity: not exclusive; Territorial scope: 129 low- and middle-income countries
Sources
- Licence agreement: MPP and Quality Chemical Industries Limited (executed sublicence, baloxavir marboxil), Medicines Patent Pool, 2026-09-16
- Qcil and Medicines Patent Pool Sign Sublicense to Expand Access to Influenza Treatment, Qcil, 2026-09-25
- Quality Chemical expands drug manufacturing with influenza sub-licence, Daily Monitor (Uganda), 2026-09-30
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.
